A Patient's Concern About Frequent MRI Scans
In a letter to the medical advice column 'Dear Doctor,' a reader identified only as J.D. describes significant anxiety over a recent diagnosis. An MRI performed for unrelated reasons, followed by an endoscopic ultrasound, revealed a cluster of small cysts (3-7 mm) in the pancreas, suspected to be branch-duct intraductal papillary mucinous neoplasms (IPMNs). The patient's main pancreatic duct is mildly enlarged.
J.D.'s doctors have recommended an MRI/MRCP with and without contrast in six months, followed by ongoing monitoring every six months to two years. While the patient was told that IPMNs are precancerous but usually do not progress to cancer, the prospect of frequent, lengthy MRIs and long-term cancer surveillance feels overwhelming. The patient asks whether such intense monitoring is truly necessary for cysts this small, or if it is overly aggressive, and whether safer alternatives like shorter, non-contrast scans exist to ease the testing burden.
Doctor's Response: Risk and Rationale
In response, Dr. Roach acknowledges that IPMNs can progress to pancreatic cancer, which is why doctors want to keep a careful eye on them. He notes that there are several guidelines on managing these cysts. The main risk factor for developing cancer is the size of the cyst, but a dilated main pancreatic duct is also a worrisome feature according to the guidelines.
Dr. Roach explains that because of the dilated duct, the risk of developing cancer in the next five years is about 10%. He points out that while this means 90% of the time cancer will not develop, doctors can find and potentially cure one person for every 10 people who agree to careful follow-up.
He advises against CT scans, which are not as accurate and have the downside of ionizing radiation. While he understands that MRIs take a long time and can be very noisy, he recommends following the doctors' suggestions for follow-up scans, stating that the risk is high enough to add his recommendation to theirs.
Dr. Roach also recommends CA19-9 blood testing. If the main pancreatic duct enlarges over time, by more than 2 mm per year, he suggests a surgical consultation.
Weighing the Burden of Surveillance
The column highlights a tension between the psychological burden of long-term monitoring and the medical necessity driven by a specific risk factor. The patient's anxiety is grounded in the incidental discovery and the prospect of indefinite testing, while the doctor's advice emphasizes the potential to catch and cure a cancer that might otherwise go undetected. The doctor's response aims to reassure the patient that the surveillance is a precautionary measure, not an overreaction, given the elevated risk associated with the dilated main pancreatic duct.